Axsome Therapeutics Inc.

05/09/2022 | Press release | Distributed by Public on 05/09/2022 05:17

Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea